2026-04-17T02:43:15Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/117162025-10-24T10:20:32Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Esteban, Luis M.
author
Borque Fernando, Ángel
author
Picola Brau, Natalia
author
Muñoz-Rodriguez, Jesus
author
Paesano, Nahuel
author
Miro, Berta
author
Celma, Ana
author
Morote Robles, Juan
2025-10-24T10:20:32Z
2025-10-24T10:20:32Z
2024-07-16T12:21:35Z2024-07-16T12:21:35Z2024-07-10
http://hdl.handle.net/11351/11716
5-alpha reductase inhibitor; Predictive model; Prostate cancerInhibidor de la 5-alfa reductasa; Modelo predictivo; Cáncer de próstataInhibidor de la 5-alfa reductasa; Model predictiu; Càncer de pròstataPurpose
To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI).
Materials and methods
A population of 2,212 men with prostate-specific antigen serum level > 3.0 ng/ml and/or a suspicious digital rectal examination who underwent multiparametric MRI and targeted and/or systematic biopsies in the year 2022, at ten participant centers of the Catalonian csPCa early detection program, were selected. 120 individuals (5.7%) were identified as receiving 5-ARI treatment for longer than a year. The risk of csPCa was retrospectively assessed with the Barcelona-risk calculator 2 (BCN-RC 2). Men undergoing 5-ARI treatment for less than a year were excluded. CsPCa was defined when the grade group was ≥ 2.
Results
The area under the curve of the BCN-MRI PM in 5-ARI naïve men was 0.824 (95% CI 0.783–0.842) and 0.849 (0.806–0.916) in those receiving 5-ARI treatment, p 0.475. Specificities at 100, 97.5, and 95% sensitivity thresholds were to 2.7, 29.3, and 39% in 5-ARI naïve men, while 43.5, 46.4, and 47.8%, respectively in 5-ARI users. The application of BCN-MRI PM would result in a reduction of 23.8% of prostate biopsies missing 5% of csPCa in 5-ARI naïve men, while reducing 25% of prostate biopsies without missing csPCa in 5-ARI users.
Conclusions
The BCN-MRI PM has achieved successful validation in Catalonia and, notably, for the first time, in men undergoing 5-ARI treatment.This research was supported by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666). Open Access Funding provided by Universitat Autonoma de Barcelona.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Pròstata - Càncer - Imatgeria
Pròstata - Càncer - Tractament
Inhibidors enzimàtics - Ús terapèutic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Steroid Synthesis Inhibitors::5-alpha Reductase Inhibitors
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms
Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de la síntesis esteroidea::inhibidores de la 5-alfa reductasa
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata
Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética
External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion